Managing fibrinolysis without aprotinin.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20103278.
- Also identified by DOI 10.1016/j.athoracsur.2009.10.043.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cardiopulmonary bypass increases perioperative bleeding and produces a consumptive coagulopathy, which is defined as the simultaneous production of thrombin and fibrinolysis. Thrombin formation and fibrinolysis primarily occur in the surgical wound and peak at the time heparin is reversed by protamine. Neither aprotinin nor lysine analogs successfully control bleeding in many complex procedures, reoperations, aortic resections, or in implantations of mechanical circulatory devices. This analysis reviews the mechanisms involved and current treatment protocols, with the conclusion that changes in treatment protocols rather than use of a specific anti-fibrinolytic drug may provide better control of bleeding in these patients.
Medical subject headings
- Antifibrinolytic Agents
- Aprotinin
- Fibrinolysis
- Hemostatics
- Postoperative Hemorrhage